“Make a Difference” (MAD) is a direct continuation of the live webinar series “The Power of Prophylaxis”.

This series of eight webinars, of which 3 webinars were held in 2021 and 5 will be held in 2022/2023 , explore how clinicians can best proceed to provide optimal diagnosis and treatment to all HAE patients as early as possible. The webinars address the strategy of earlier and more comprehensive diagnostics that reduce delays in diagnosis, as well as close monitoring of therapy that enables continuous optimisation of therapeutic procedures.

Scientific director: Markus Magerl

Technical agency: Materia Prima srl

Make a Difference is initiated by ACARE and funded by Takeda Pharmaceutical Company Limited

Register NOW: MAD 10 on February 20th, 2024

TOPIC:

MODERN LONG-TERM PROPHYLAXIS AND TREATMENT OPTIMIZATION BASED ON REAL WORLD EXPERIENCE

Date: February 20th, 2024

Time: 5 pm to 6 pm CET

ACARE Make A Difference is an eleven-part webinar series with a primary focus on the diagnostic evaluation of patients experiencing recurrent angioedema, including those with hereditary angioedema (HAE), as well as the enhancement of therapy control and optimization. The overarching goal of this webinar series is to facilitate the provision of optimal therapy to all individuals afflicted with recurrent angioedema, particularly those affected by HAE, at the earliest possible stage.

Throughout the series, various topics are explored, including strategies to expedite the diagnosis process and reduce instances of misdiagnosis, methods for family screening in HAE patients, the implementation of closely monitored therapy control measures, and guidance on the continual refinement of therapeutic approaches.

This specific webinar will place special emphasis on the updated and comprehensive classification and terminology of angioedema.


TOPICS and SPEAKERS

Prof. Dr. Marcus Maurer: Introduction

Dr. Stefan Cimbollek: C1-Inhibitor and Long-Term Prophylaxis in real life.

Dr. Mauro Cancian: Lanadelumab and Long-Term Prophylaxis adaption.

Dr. Emel Aygören Pursun: Oral treatments advantages/disadvantages compared to Long-Term Prophylaxis.

All faculty: Q&A

Register now: MAD 11 on March 21st, 2024

TOPIC: Navigating HAE: A Guide to Effective Patient Management

Date: 21st of March 2024

Time: 5.00-6.00 pm CET

Prof. Dr. Marcus Maurer: Introduction and moderation

Dr. Stephen Betschel: Shared decision making in HAE

Dr. Noémi Bara: Effective communication between physician and patient

Marta Ferrer: LTP: How long is long term?

All faculty: Q&A

ACARE Make A Difference is an eleven-part webinar series with a primary focus on the diagnostic evaluation of patients experiencing recurrent angioedema, including those with hereditary angioedema (HAE), as well as the enhancement of therapy control and optimization. The overarching goal of this webinar series is to facilitate the provision of optimal therapy to all individuals afflicted with recurrent angioedema, particularly those affected by HAE, at the earliest possible stage.

Throughout the series, various topics are explored, including strategies to expedite the diagnosis process and reduce instances of misdiagnosis, methods for family screening in HAE patients, the implementation of closely monitored therapy control measures, and guidance on the continual refinement of therapeutic approaches.

MAD 9

Date: 9 November, 2023

Time: 17:00 – 18:00 CEST (Berlin +2)

Topic: UPDATED AND COMPREHENSIVE CLASSIFICATION AND TERMINOLOGY OF ANGIOEDEMA

The series is focused on the diagnostic work-up in patients with recurrent angioedema, including hereditary angioedema (HAE), therapy control and optimization and is a direct follow-up to our successful “The Power of Prophylaxis” program.

The overall aim is to help provide the optimal therapy to all patients with recurrent angioedema as early as possible, especially patients with HAE. This webinar is intended fpr healthcare professionals outside of the USA.

We have three fantastic speakers that will be educating us on the following topics:

Prof. Dr. Markus Magerl: Angioedema nomenclature and classification – The need for an update and revision.

Dr. Thomas Buttgereit: Finding consensus in angioedemology

Prof. Dr. Marcus Maurer: Unmet needs in angioedema classification.

All speakers from: Charité – Universitätsmedizin Berlin Institute of Allergology IFA & Fraunhofer ITMP Immunology and Allergology IA

MAD 8

Date: 7 February, 2023

Time: 17:00 – 18:00 CEST (Berlin +2)

Topic: HAE with Normal C1-Inhibitor (HAE-N-C1-INH)

The series is focused on the diagnostic work-up in patients with recurrent angioedema, including hereditary angioedema (HAE), therapy control and optimization and is a direct follow-up to our successful “The Power of Prophylaxis” program.

The overall aim is to help provide the optimal therapy to all patients with recurrent angioedema as early as possible, especially patients with HAE. This webinar is intended fpr healthcare professionals outside of the USA.

We have four fantastic speakers that will be educating us on the following topics:

Prof. Dr. Marcus Maurer – Introduction

Prof. Emeritus Anastasios E. Germenis – Genetics, epidemiology and geographical distribution of HAE-n-C1-INH

Prof. Dr. Konrad Bork – Clinical features of HAE-n-C1-INH

Prof Dr. Laurence Bouillet – Treatment approaches and treatment outcomes

MAD 7 

Date: 29 November 2022

Time: 17:00 – 18:00 CEST (Berlin +2)

Topic: Short Term Prophylaxis

Where: Online

The series is focused on the diagnostic work-up in patients with recurrent angioedema, including hereditary angioedema (HAE), therapy control and optimization and is a direct follow-up to our successful “The Power of Prophylaxis” program.

The overall aim is to help provide the optimal therapy to all patients with recurrent angioedema as early as possible, especially patients with HAE. This webinar is intended fpr healthcare professionals outside of the USA.

We have five fantastic speakers that will be educating us on the following topics:

Prof. Dr. Marcus Maurer – Introduction

Prof. Dr. Henriette Farkas – Which interventions require short term prophylaxis?

Prof. Dr. Vesna Grivcheva-Panovska – Which drugs can be used for short term prophylaxis?

Dr. Andrea Zanichelli – Short term prophylaxis: real life observations

Prof. Dr. Markus Magerl – Short term prophylaxis on top of long term prophylaxis?

MAD 5
36 participants – 21 countries

MAD 6
103 participants – 37 countries

MAD 3
108 participants – 33 countries

MAD 4
130 participants – 31 countries

MAD 1
78 participants – 36 countries

MAD 2
106 participants – 25 countries